Login
$KPTI
$0.02 -$0.00 (7.47%) After hours

$KPTI SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 NT 10-Q
12 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

03 Nov 2026 8-K: Entry into a Material Definitive Agreement; Bankruptcy or Receivership +4 more

Certain portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

02 Nov 2026 8-K: Regulation FD Disclosure

– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis –

28 Oct 2026 SCHEDULE 13G/A
22 Oct 2026 8-K: Other Events

As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indenture...

19 Oct 2026 Form 4: Abate Kristin, Chief Accounting Officer

Sold 4,788 shares ($1.65K)

14 Oct 2026 8-K: Other Events

As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10,...

08 Oct 2026 SCHEDULE 13G/A
02 Oct 2026 Form 4: Abate Kristin, Chief Accounting Officer

Sold 378 shares ($450)

25 Sep 2026 SCHEDULE 13G/A
25 Sep 2026 SCHEDULE 13G/A
18 Sep 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year

On September 17, 2026, the Pricing Committee of the Board of Directors of Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), acting pursuant to authority delegated to it by the Board of Directors on September 10, 2026 ...

11 Sep 2026 8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate a Financial Obligation +2 more

This Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026 (this “Agreement”), is entered into by and among (i) Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”) and each of the undersi...

04 Sep 2026 SCHEDULE 13G
02 Sep 2026 Form 4: Abate Kristin, Chief Accounting Officer

Sold 19 shares ($38.4)

31 Aug 2026 8-K: Other Events

On August 31, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced that it has submitted a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) seeking Accelerated Approval for XPOVIO® (seli...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support